CISN - The OMICS Revolution and Beyond - Personalized Medicine - pg 9
| You Are Here: Home > Cancer Research > What We Know About Cancer > OMICS Revolution > Personalized Medicine - pg 9 |
Personalized Medicine - page 9CISN Summary Of Personalized Medicine SectionCancer researchers define the term 'personalized medicine' as: "A process that analyzes a person's molecular information to determine the person's propensity for developing certain diseases, including a disease's potential onset and course. It also determines a person's propensity for responding to different drug therapies, by determining a patient's ability to metabolize drugs and/or likelihood of experiencing adverse drug reactions. The term personalized medicine is often used in place of the scientific term pharmacogenomics." - Quote from Jennifer Miller,PhD (Bioethicist) Clinicians, healthcare specialists and advocates define the term more broadly and include all relevant clinical and environmental exposure information added to an individual's molecular profile. Although personalized medicine is not yet ready for everyday use on a broad scale, research advances are rapid and the hope is that the science will move forward quickly so it can be in the clinic soon. Some examples are already in use and others will be as they move through clinical trials. A. Personalized medicine offers a structural model for efficient healthcare.
|
| Section Index | |
| ● | What We Know About Cancer |
| How Cancer is Studied | |
| Drug Development | |
| New Treatments | |
| Research Advocacy | |
B. Personalized medicine covers all the bases
Cancer is a collection of more than 100 different diseases, and, for most cancers, the molecular characteristics have not been fully classified and there are no known or validated markers for early detection, treatment planning, or targeted therapy. The diagnosis of cancers is still based largely on morphological examination of tumor biopsy specimens, as it has been for decades, but this approach has significant limitations for predicting a given tumor's potential for progression and response to treatment. Personalized medicine hopes to change this. C. Important public policy issues around personalized medicine Because personalized medicine relies on the collaboration of drug and device companies, new standards will be needed for the approval and reimbursement process of the newly created drug-device combinations.
D. Personalized medicine includes clinical, 'OMIC' and environmental information Remember personalized medicine is 'about you'. That means all of your traditional clinical medical information, combined with your 'OMIC' information and influenced by your interaction with your environment. E. Stakeholders: It will be essential for diagnostics and pharmaceutical companies, payers, physicians, and patient groups to interact to create an environment that is favorable to both the basic research that is required for innovation of effective personalized medicine solutions, as well as their eventual commercialization.
You have reached the end of this section. If you wish to test your knowledge of "What We Know About Cancer"For more information about our e-Training courses, please read the e-Quiz Introduction. |


